

February 27, 2014



## Rigel Announces Participation at Two Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that company management will present at two upcoming investor conferences. Details of the events are as follows:

Cowen and Company 34<sup>th</sup> Annual Health Care Conference

Date – March 3, 2014 at 2:50 p.m. ET

Location – Boston, MA

Presenter – Ryan Maynard, Executive Vice President and Chief Financial Officer

26<sup>th</sup> Annual ROTH Conference

Date – March 11, 2014 at 2:00 p.m. PT

Location – Dana Point, CA

Presenter – James M. Gower, Chairman and Chief Executive Officer

Both events will be webcast live and can be accessed at [www.rigel.com](http://www.rigel.com). Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

### About Rigel ([www.rigel.com](http://www.rigel.com))

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The Company currently has five product candidates in development: fostamatinib, an oral SYK inhibitor expected to enter Phase 3 clinical trials for ITP and a Phase 2 clinical trial for IgA nephropathy in the first half of 2014; R348, a topical JAK/SYK inhibitor currently in Phase 2 clinical trials for dry eye; R118, an AMPK activator entering Phase 1 in early 2014; and two oncology product candidates in Phase 1 development with partners BerGenBio and Daiichi Sankyo.

Contact: Ryan Maynard

Phone: 650.624.1284

Email: [invrel@rigel.com](mailto:invrel@rigel.com)

SOURCE Rigel Pharmaceuticals, Inc.

